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ABSTRACT 
 
Prostate cancer (PCa) is an incredibly common disease in the United States, with 
approximately 170,000 new diagnoses and 30,000 deaths occurring on an annual basis. 
The current mainstay of treatment for PCa is known as androgen deprivation therapy 
(ADT), which has proven to be an effective short-term option in earlier stages of the 
disease. Unfortunately, longer periods of ADT risk accelerating progression of the cancer 
to the point where 25% of all treated patients relapse to an incurable, metastatic, and 
highly lethal form known as castration-resistant prostate cancer (CRPC). In 
approximately 60% of CRPC cases, a splice variant of androgen receptor called AR-V7 
can be detected and has been shown to contribute to this progression.  
Recent studies have shown that resveratrol (RSV) is capable of increasing the 
polyubiquitination and subsequent proteasomal degradation of ARV7 proteins in CRPC 
cells, though the mechanism behind this effect remains unknown. To investigate the 
hypothesis that this may occur via downregulation of DBC1 proteins which normally 
blocks the polyubiquitination site on AR-V7, 22RV1 cells were cultured and treated with 
varying concentrations of RSV for up to 24 hours. Results showed that RSV post-
transcriptionally downregulates levels of DBC1 while reducing levels of AR-V7 proteins 
and the expression of its target genes. N-cadherin, a known target gene of AR-V7, was 
also shown to be downregulated by RSV in a statistically significant and dose-dependent 
manner at the mRNA and protein levels. RSV was shown to simultaneously increase 
levels of E-cadherin proteins and mRNA in a statistically significant and dose-dependent 
manner, suggesting it may be capable of inhibiting or preventing the epithelial-to-
2 
mesenchymal transition (EMT) in CRPC cells. Together, these findings implicate RSV as 
a promising therapeutic option for the majority of CRPC patients who are ARV7-
positive. 
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INTRODUCTION 
 
1.1 Background: prostate cancer diagnosis & treatment 
Prostate cancer (PCa) is an incredibly common disease in the United States, with 
approximately 170,000 new diagnoses and 30,000 deaths occurring on an annual basis.1 
As the second most common cancer in males, 1 out of every 9 American men will be 
diagnosed with prostate cancer at some point in their lives and 1 in 41 will die from the 
disease.1  
Although the overall rate of prostate cancer in the US is declining, the steady rise 
in number of diagnoses each year is largely the result of increasing population and 
improved diagnostic techniques which allow for earlier detection of the disease before 
symptoms arise.2 The most common and widely utilized of these techniques is the 
prostate-specific antigen (PSA) assay. However, earlier detection has not reduced the 
number of deaths from the disease.2,3 Though there are a number of factors such as age 
and growth rate that can influence which treatment options are available to patients, one 
of the primary determinants is the stage of the cancer at diagnosis (Figure 1).4 
In the early preclinical stages of prostate cancer, an effective first option for many 
is watchful waiting, during which a physician will temporarily forgo treatment and 
closely monitors the cancer’s progression until it is deemed necessary to pursue more 
aggressive treatments such as surgery or radiotherapy. In some cases of PCa, the cancer 
can progress so slowly that the patient will never experience any symptoms, and they can 
forgo treatment altogether. For the remainder of cases, however, the varying risk of 
permanent side effects such as urinary incontinence or impotence—which largely depend 
7 
upon the skill of the surgeon—make these more aggressive options less than ideal.1,4 
While the tumor is still confined to the interior of the prostate, radical prostatectomy—a 
procedure which involves complete removal of the gland and surrounding tissue—is the 
most effective curative treatment available, though hormone therapies remain the primary 
treatment option for prostate cancer (Figure 1).  
Figure 1. Standard treatment options by stage in prostate cancer (PCa). 
 
Hormone therapy or androgen deprivation therapy (ADT) is often an effective 
short-term option for many with early stage PCa, however prolonged treatment has 
shown no association with improved patient outcome and in some cases has even been 
found to accelerate progression of the cancer.5 As it stands, around 25% of PCa patients 
treated with ADT relapse within 3 years to a much more advanced, aggressive, and 
metastatic form known as castration-resistant prostate cancer (CRPC).6,7 There are 
currently no reliable curative treatments for prostate cancer once it becomes castration-
resistant and what limited therapeutic options remain such as chemotherapy and 
immunotherapy have only proven effective at prolonging life by a few months.8 Clearly, 
8 
there is a demand for new and better therapeutic options for patients diagnosed with 
progressive forms of prostate cancer and CRPC. 
1.2 Mechanisms of PCa progression & Androgen Deprivation Therapy 
Androgen & androgen receptors (AR) play a key role in the growth and 
maintenance of a healthy prostate, but they can also be among the primary culprits behind 
the development and progression of prostate cancer. The androgen receptor (AR-FL) is a 
protein in prostate cells comprised of three primary functional domains (Figure 2). At the 
N-terminal is a transactivation domain (NTD) which facilitates regulation of canonical 
AR target genes responsible for cell maintenance, proliferation, and survival.6,9 Adjacent 
to the NTD is the receptor’s primary DNA-binding domain (DBD), followed by a hinge 
region which allows homodimerization to other AR when activated.9 Finally, the ligand-
binding domain (LBD) at the C-terminus contains the binding site for androgens and will 
keep the receptor in an inactive state unless the androgen is bound.9 
 
Figure 2. Protein structures and functional domains of AR-FL and AR-V7. 
In both the full-length androgen receptor (AR-FL) and AR-V7, functional domains include the n-
terminal domain (NTD) responsible for transcriptional activity and DNA-binding domain (DBD) 
facilitating DNA-protein binding to androgen response elements (AREs). AR-FL contains a hinge 
region to facilitate homodimerization to AR and a ligand binding domain (LBD) which house the 
androgen binding site. In AR-V7, both the hinge region and LBD are missing, resulting in 
androgen-independence. 
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In healthy prostate tissue, androgen hormones such as testosterone that are 
synthesized in the testes and adrenal glands will enter cells where they are then converted 
into a more potent form known as 5α-dihydrotestosterone (DHT). The androgens or DHT 
can then bind to inactive AR located within the cytoplasm (Figure 3a).5 Binding of the 
androgen ligand to AR serves as its activation signal, mobilizing the receptor to dimerize 
with another activated AR to form the homodimer which can then translocate to the 
nucleus.5 Once there, the DBD binds to specific DNA sequences known as androgen 
response elements (AREs) located within the enhancer/promoter regions of canonical AR 
target genes.5,10 The NTD then recruits various transcription factors and alters the 
expression of those genes.5  
One protein produced and secreted by this signaling pathway is prostate-specific 
antigen (PSA). In the development of PCa, gradual overactivation of AR causes 
dysregulated growth of cells within the prostate and also increases the expression of 
PSA.5,9 Increased levels of PSA in the bloodstream is one of the primary markers for 
prostate cancer. If left to progress, this can result in tumorigenesis and eventually spread 
to other parts of the body. Amplification and/or mutations in the AR gene, 
overexpression of coactivators, and alternative splicing are all mechanisms by which this 
gradual AR overactivation can occur.11 
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In general, treatment with androgen deprivation/hormone therapy targets AR and 
deprives the androgen hormone serving as its activation signal.6,10 Enzalutamide and 
Abiraterone, two of the major drugs used in ADT, function by blocking the hormone 
binding site on AR itself or by inhibiting the body’s ability to synthesize androgens, 
respectively (Figure 3b).5  
Figure 3. Androgen/AR signaling in prostate cancer and mechanisms of androgen 
deprivation therapy (taken from Nelson et al.).5 
Androgen hormone in prostate cancer cells binds over-activated androgen receptors (AR) causing 
homodimerization and translocation to the nucleus. Activated nuclear AR homodimers regulate 
transcriptional activity of the cells, facilitating a dysregulated increase in proliferation, survival, 
and secretion of prostate-specific antigen (PSA)(A). Androgen deprivation therapy (ADT) 
restricts cancer cell response to AR overactivation by inhibiting androgen-AR interaction. 
Enzalutamide and Abiraterone are two major drugs used in ADT which function via competitive 
inhibition at the androgen binding site or inhibition of the body’s de novo synthesis of androgen 
hormone, respectively (B). 
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Eventual progression of prostate cancer most often occurs via upregulation of AR 
splice variants less dependent on androgen as the body tries to adapt to the stresses 
imposed by prolonged androgen deprivation.5 By far the most prevalent of these 
variations, detected in over 60% of CRPC diagnoses, is known as AR-V7.7 This mutation 
generates a truncated but constitutively-active form of the AR that completely lacks the 
ligand binding domain, allowing it to function without dependence on the androgen 
hormones targeted by ADT (Figure 2).12  
Expression of AR-V7 within PCa tissues can be detected by core needle biopsy of 
the prostate, and has been associated with decreased survival, shorter progression time to 
CRPC, and higher rate of recurrence even after radical prostatectomy.1,7 Overexpression 
of AR-V7 has also shown to be strongly associated with older age (>70 y/o) at diagnosis 
meaning that, like prostate cancer, age is a prominent risk factor.13 One reason for this 
may be the gradual decline in testosterone synthesis that typically occurs as men age, 
given that physiological androgen levels show an inverse correlation with AR-V7 
expression.14 Seeing as AR-V7 is detected in a majority of CRPC cases7, this would be 
consistent with other studies which have shown that patients with CRPC who exhibit 
higher (>5 ng/dl) serum androgen levels are significantly more likely to benefit from 
ADT than those with lower (<5 ng/dl) levels of androgen.15 
1.3 Survey of current research and study aims 
Recently, a critical coactivator for AR-V7 in CRPC cell lines was identified as 
deleted in breast cancer (DBC1), an AR-FL cofactor which preferentially associates with 
AR-V7 and enables it to perform a wide variety of its functions commonly-linked to 
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CRPC progression and metastasis.6 One such function specific to AR-V7 is the selective 
recruitment to and increased DNA binding affinity for the CDH2 enhancer region upon 
association with DBC1 (Figure 4). Once AR-V7 binds the enhancer, the associated DBC1 
portion undergoes a conformational change and interacts with the CDH2 promoter region 
~20 kb upstream to form a chromatin loop. From this structure, DBC1 facilitates 
numerous long-distance chromatin interactions which enable and upregulate transcription 
of CDH2.6  
The CDH2 gene encodes the N-cadherin protein that is well-established as one of 
two primary drivers of the Epithelial-to-Mesenchymal Transition (EMT).6,16 This 
mesenchymal marker of EMT is commonly upregulated in CRPC and other metastatic 
cancers.6 Cancer cells which undergo this transition exhibit increased migratory capacity, 
invasiveness, and a heightened resistance to apoptosis.17 In prostate cancer specifically, 
the increase in expression of N-cadherin is considered to be one of the major causes of 
progression to metastasis and the development of castration-resistance in CRPC.6,16,18 
Once the transitioned cancer cells have adopted the more mesenchymal phenotype, they 
can more readily detach from the primary tumor and spread throughout the body. 
Eventually, they revert to the more adhesive epithelial phenotype through what is known 
as the mesenchymal-to-epithelial transition (MET) and attach themselves at peripheral 
sites, where they can begin proliferating to form the secondary tumor.    
Although the role of androgens in regulating N-cadherin is not yet known, lower 
testosterone levels and therapeutic treatment with androgen deprivation has been strongly 
associated with its upregulation.18 In addition to this, N-cadherin/CDH2 expression 
during the epithelial-to-mesenchymal transition is reciprocally paired to that of CDH1—a 
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gene which encodes E-cadherin, the other major driver of EMT and the primary cell-cell 
adhesion molecule in epithelial cells.17 Although the upregulation of N-cadherin is still 
required, downregulation of E-cadherin must also occur before EMT can initiate.19  
Like CDH2/N-cadherin, another target gene which is shown to be upregulated by 
AR-V7, but not the full-length AR, is the ubiquitin-conjugating enzyme E2C 
(UBE2C).20,21 This enzyme within the ubiquitin-proteasome pathway functions by 
initiating the polyubiquitination and degradation of anaphase-promoting 
complex/cyclosome (APC/C) substrates which are crucial to proper chromosome 
segregation and the progression of mitosis.22,23 As of 2019, overexpression of UBE2C has 
been detected in over 27 different forms of cancer.23 In PCa specifically, increased 
expression of UBE2C is directly correlated with increased AR-V7 expression, and has 
been associated with shorter overall survival (OS) times, poorer clinical outcomes, and 
can indicate tumor progression.21,23 For this reason, it has become a firmly established 
therapeutic target in the treatment of many different cancers and diseases.23  
An additional function of DBC1 is increasing the stability of AR-V7 by 
occupying the same binding site used by the E3 ubiquitin ligase known as C-terminus of 
Hsc70-interacting protein (CHIP). In this way, DBC1 effectively competes with the only 
enzyme currently known to polyubiquitinate AR-V7 and subsequently target it for 
proteasomal degradation (Figure 4).6 Given the enormous prevalence of PCa among men 
and the relative lack of long-term treatment options for those with CRPC, any methods 
which can combat the underlying causes of CRPC progression such as AR-V7 or DBC1 
are well worth pursuing.  
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Figure 4. Schematic showing competitive binding of DBC1 to AR-V7. 
Formation of DBC1-ARV7 protein complex leads to increased protein stability and DNA-binding 
affinity for AR-V7 target genes (ex. CDH2) associated with increased metastatic potential. Bound 
DBC1 competitively blocks the binding site for an E3 ubiquitin ligase known as C-terminus of 
Hsc70-interacting protein (CHIP), preventing polyubiquitination and subsequent proteasome 
degradation. Created using Figure 6j from Jin Moon et al.6 
 
         Resveratrol (RSV, trans-3,4,5-trihydroxystilbene) is one such factor investigated for 
its chemopreventative effects in a wide array of cancers, including PCa.24 RSV is a 
polyphenolic phytoalexin—a compound released by certain plants when under duress—
that is most commonly found in red grape skins, blueberries, and even peanuts.24 In a 
recent study, RSV was found to reduce levels of endogenous AR-V7 proteins and the 
corresponding expression of its target genes without affecting levels of the full-length AR 
in several different ARV7-positive CRPC cell lines.20  RSV was shown to mediate this 
downregulation in a dose-dependent manner by enhancing the polyubiquitination and 
subsequent proteasomal degradation of AR-V7 proteins.20 The specific nature of the 
mechanism(s) by which RSV mediates this effect on AR-V7 has yet to be determined.  
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Given this, and the lack of knowledge regarding the effects of resveratrol on 
DBC1, I hypothesize that RSV increases polyubiquitination and degradation of AR-V7 
by affecting relative levels of CHIP ubiquitin ligase and/or DBC1, which competes with 
it for binding to AR-V7.25 If this is determined to be the case, then treatment with 
resveratrol may also function as a mechanism for decreasing the levels of CDH2/N-
cadherin in PCa cells, given that it requires DBC1 for its expression.6  
16 
 
MATERIALS & METHODS 
 
Reagents 
RPMI (1X) with L-glutamine culture media was purchased from Corning Cellgro and 
stored at 4oC. Premium Fetal Bovine Serum (FBS) was purchased from Atlanta 
Biological (Oakwood, GA) and stored at -20oC. Antibiotic-Antimycotic (100X) was 
purchased from Life Technologies and stored at 4oC. Dulbecco’s phosphate-buffered 
saline (DPBS) was purchased from Gibco Life Technologies (w/o CaCl/MgCl). Trypsin 
(0.25%) was purchased from Corning Cellgro and stored at -20oC (without bicarbonate, 
0.1% EDTA in HBSS). Resveratrol (RSV) was purchased from Sigma-Aldrich and stored 
in the dark at -30oC. 200mM stock solutions of RSV were prepared by dissolving 
resveratrol in 100% EtOH (Biotechnology Grade Anhydrous-Alcohol, IBI Scientific, 
Peosta, IA). Both the cycloheximide (CHX) solution, and rabbit anti-CHIP antibodies 
were purchased from Sigma-Aldrich and stored in the dark at -20oC.  
From Invitrogen, 0.1M DTT and First-strand buffer (5X) were purchased and stored 
at -20oC. Both Random 9-mer primers purchased from Agilent Technologies and ROX 
Reference Dye II purchased from Takara were stored at -20oC. 10 mM dNTP mix and 
TaqMan qPCR primers for CCAR2, CDH1, CDH2, UBE2C, KLK3, and GAPDH were 
purchased from Thermo-Fisher Scientific and stored at -20oC.  
From Bio-Rad Laboratories, Tris/Glycine/SDS Electrophoresis Buffer (10X), 
Precision Plus WesternC Protein Standards (stored at -20oC), Precision Protein 
StrepTactin-HRP Conjugate (stored at 4oC), Clarity and Clarity Max Western ECL 
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substrates were purchased. Ponceau S Total Protein Stain was purchased from Boston 
Bio Products. DBC1, ARV7, N-Cadherin, E-Cadherin, and GAPDH antibodies were all 
purchased from Abcam and stored at -20oC. 
Cell Culture 
22RV1 cells obtained from ATCC Bioproducts were cultured in RPMI 1640 1X 
with L-glutamine (Corning), 10% premium FBS (Atlanta Biological), and 1% Antibiotic-
Antimycotic (Thermo-Fisher Scientific). Cells were grown in either 10 cm culture dishes 
(CellTreat) with 10 mL of growth media or 6-well culture plates (CellTreat) with 2 mL of 
growth media replaced every 1-2 days. Cells were kept in incubators at 37oC and 5% 
CO2, washed briefly with 1X DPBS (Gibco), and passaged at approximately 70-90% 
confluence with 0.25 % trypsin (Corning). Cells were counted using a Countess II digital 
cell counter purchased from Life Technologies. Countess cell-counting chamber slides 
and Trypan Blue stain were purchased from Invitrogen. 
Cell Treatment 
At approximate cell counts of 1 million and 5 million cells, 22RV1 cells were 
incubated at 37oC and allowed to adhere to 10 cm cell culture dishes or 6-well culture 
plates, respectively, for 24 hours prior to treatment. Preparation of resveratrol treatments 
was carried out through serial dilution of 200 mM RSV stock solution to 25 µM, 50 µM, 
75 µM, and 100 µM in 1X RPMI 1640 growth media (Corning). Preparation of 
cycloheximide (CHX) treatments was carried out through serial dilution of 100 mg/mL 
ready-made cycloheximide solution (Sigma Aldrich, SKU ID# C4859) to 50 nM and 50 
µM in 1X RPMI 1640 growth media. Cells were treated for up to 24 hours. Following 
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treatment, all cells were scraped, collected, and pelleted by centrifuge at 3000 RPM and 
1000 RPM. Excess media was aspirated and cell pellets were stored at -30oC prior to 
RNA purification or preparation of whole cell lysates.  
Total RNA Purification 
RNA from harvested cell pellets was purified using RNeasy Plus Micro 
Purification Kit (Qiagen) in accordance with manufacturer protocol. RNeasy columns 
(Qiagen) were used to extract RNA with two elutions of RNase-free H2O (Qiagen) 
followed by a 1-minute spin at 15,000 RPM after each elution. Total RNA quantification 
was performed using a NanoDrop 2000c UV-Vis Spectrophotometer purchased from 
Thermo-Fisher Scientific and samples were stored in the dark at -30oC. 
Reverse Transcription-PCR 
Before cDNA generation, 10 mM dNTPs (Thermo-Fisher Scientific), random-9-
mer primers (Agilent), and RNase-free water (Qiagen) were added to 5 µg of sample 
RNA and incubated in a Techne thermal cycler for 5 minutes at 65oC. Superscript II 
Reverse Transcriptase Kit (Invitrogen) was then used to generate cDNA in accordance 
with manufacturer protocol. PCR reactions were carried out in a 3Prime Techne thermal 
cycler using the following run method: primer annealing (10 minutes at 25oC), primer 
extension (50 minutes at 42oC), and primer inactivation (15 minutes at 70oC.) 76 µL of 
nuclease-free H20 (Thermo-Fischer) was added to the resulting cDNA samples which 
were then stored at -20oC. 
Quantitative Real-Time PCR 
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qPCR reactions were carried out using TaqMan Universal PCR kit (Applied Biosystems).  
in accordance with manufacturer’s protocols. The master mixes were made using [] µg 
cDNA, RNase-free H2O (Qiagen), TaqMan qPCR premix, ROX II Reference Dye 
(Thermo-Fisher Scientific), and appropriate qPCR probes. From Thermo-Fisher 
Scientific, target primers were purchased for CCAR2/DBC1(human, Primer ID# 
Hs00377763_CE), CDH1/E-cadherin (human, Primer ID# Hs00345541_CE), CDH2/N-
cadherin(human, Primer ID# Hs00174449_CE), and UBE2C(human, Primer ID# 
Hs00215129_CE) alone or in multiplex with GAPDH(human, Catalog ID# 402869), the 
housekeeping gene used as an endogenous control. 25 µL of master mix was loaded in 
triplicate or quadruplicate into each well of a 96-well qPCR reaction plate (Applied 
Biosystems), capped with 8-strip tube caps (Applied Biosystems), centrifuged for 30 
seconds, and analyzed using the StepOne Plus Real-Time PCR System (Applied 
Biosystems) with the following run method over 40 cycles: hot start (30 seconds at 
95oC), denature (5 seconds at 95oC), and extension (37 seconds at 60oC).  
Whole Cell Lysate Preparation & Quantification 
Harvested cells were resuspended in either 50 or 100 µL of 
radioimmunoprecipitation assay (RIPA) lysis buffer depending on pellet size, vortexed, 
and left on ice for 15 minutes to lyse. Following lysis, samples were kept at 4oC and 
centrifuged for 30 minutes at 15,000 RPM. The supernatant lysates were then transferred 
to new sample tubes and stored at -30 oC while remaining cellular debris was discarded. 
Pierce BCA Protein Assay Kit purchased from Thermo-Fisher Scientific was used in 
accordance with manufacturer’s protocols to determine total protein concentration of 
each lysate. 
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Protein Gel Electrophoresis & Western Blot 
Protein samples were prepared using 25-50 µg of total protein, reagent-grade 
double distilled (RGDD) water, and sodium dodecyl sulfate (SDS) loading buffer. 
Samples were denatured at 95oC for 5 minutes, then separated by SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) (5% stacking, 10% separating) running at 125mV for 2 
hours. Following separation, bands were transferred to mini nitrocellulose membranes 
purchased from Biorad using iBlot gel transfer stacks (Thermo-Fisher Scientific) in 
accordance with manufacturer protocols. Successful band transfer was verified using 
Ponceau S total protein stain (Boston Bio Products), which was removed by washing in 
1X TBS for 10 minutes.  
Membranes were blocked with Fast Western AB Diluent (Thermo-Fisher 
Scientific) for 1 hour, washed twice with 1X TBS-Tween (0.1%) for 10 minutes each, 
and incubated overnight in primary antibody dilution at 4oC. Antibodies against ARV7 
(rabbit recombinant monoclonal, ID# ab198394) , DBC1 (rabbit monoclonal, ID# 
ab128890), E-cadherin (mouse monoclonal, ID# ab1416), and N-cadherin (rabbit 
polyclonal, ID# ab76057) were purchased from Abcam and used at 1:1000 dilution, while 
CHIP (rabbit polyclonal, ID# C9243) was purchased from Sigma-Aldrich and was used 
at 1:5000 dilution. Antibody against GAPDH (rabbit recombinant monoclonal, ID# 
ab181602) was also purchased from Abcam and was used as a loading control at a 1:1000 
dilution. Membranes were then washed 3x for 10 mins in TBS-T(1X), incubated in 
secondary antibody conjugated to HRP (Biorad) for 15 minutes at 4oC, washed another 
3x for 10 mins in TBS-T(1X), and given a final 10 min wash in TBS(1X). Pierce Fast 
Western Blot ECL Substrate (stored at 4oC) and Fast Western Optimized HRP Reagent 
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were purchased from Thermo-Fisher Scientific. Clarity Max Western ECL kit solutions 
purchased from Biorad were then introduced in a 1:1 mixture to visualize protein bands 
using a Biorad ChemiDoc MP Imager. Band intensities were quantified and normalized 
to GAPDH using ImageLab software according to manufacturer protocols (Biorad).  
Statistical Analysis 
SPSS software purchased from IBM was used for statistical analysis of relative 
quantification (RQ) values in all qPCR experiments. Significant difference among all 
treatment groups was first determined using one-way ANOVA with an alpha of 0.05. 
Following statistically significant one-way ANOVA, differences between individual 
sample groups were then determined using post-hoc Tukey HSD multiple comparisons 
analysis.  
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                                          RESULTS 
 
1.1 The effects of resveratrol on the mRNA levels of DBC1 
In a previous study, RSV was found to be able to reduce AR-V7 transcriptional 
activity and the expression of its target genes without impacting levels of AR-V7 
mRNA.20 As a target gene of AR-V7 but not the full-length AR, expression of UBE2C 
has also shown to be reduced at both the mRNA and protein levels upon treatment with 
RSV.20,21 What is not yet known is whether DBC1 also exhibits this downregulation 
under the same conditions and, if so, whether that decrease might play a role in RSV-
mediated AR-V7 degradation. 
In order to investigate the effects of RSV on DBC1 mRNA, 22RV1 cells 
expressing high levels of AR-V7 and low levels of AR-FL20 were cultured and treated 
with or without 25-100µM of RSV for a period of 24 hours. qPCR was performed using 
ΔΔCT method to measure the relative quantification (RQ) of DBC1 mRNA as the target 
gene, UBE2C as a positive control, and GAPDH as an internal control.  
As seen in figure 5a, UBE2C mRNA levels showed little to no change at 25 µM 
RSV when compared to the untreated sample but exhibited statistically significant and 
dose-dependent decreases when treated with concentrations of 50 µM, 75 µM, and 100 
µM RSV. This decrease was expected and is consistent with results obtained by Wilson 
et al.20 Additionally, this downregulation is consistent with the previously established 
RSV-mediated decrease in AR-V7 and its transcriptional activity, suggesting that this 
effect had successfully been replicated in my experiment.20 Under the same conditions, 
however, mRNA levels of DBC1 exhibited no statistically significant difference across 
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the four concentrations of RSV when compared to the untreated sample (Figure 5b). This 
suggests that RSV does not affect DBC1 mRNA levels.  
 
Figure 5. RSV induces dose-dependent decrease in UBE2C but does not alter mRNA 
levels of DBC1. 
22RV1 cells were cultured and treated with serial dilution of 25-100µM RSV for 24 hours. qPCR 
was performed in quadruplicate with GAPDH as endogenous control in multiplex with the target 
genes. Quantities of target mRNAs relative to untreated controls were calculated by ΔΔCT 
method and expressed as mean +/- SEM with CT SD <0.1. Graphs show results from three 
independent experiments (n = 3). Statistical significance was determined by post-hoc Tukey HSD 
multiple comparisons analysis following statistically significant 1-way ANOVA: *, p<0.05; **, 
p<0.001.  Relative levels of UBE2C mRNA as an established AR-V7 target genes showed 
significantly decreased levels at 50, 75, and 100µM RSV (A). Relative levels of DBC1 mRNA 
showed no significant difference across all treatment groups (B). 
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1.2 Resveratrol down-regulates protein levels of DBC1 
Similar to the effects on AR-V7, any resveratrol-mediated downregulation which 
may occur in DBC1 does not appear to affect its expression at the mRNA level. In AR-
V7, however, downregulation was established to occur post-translationally via increased 
polyubiquitination and subsequent proteasomal degradation.20 Though the specific 
mechanisms behind this effect have yet to be discovered, both the downregulation of 
DBC1 and the upregulation of CHIP remain plausible mechanisms for this increase in 
AR-V7 polyubiquitination.  
To investigate the overall effects of RSV on these two proteins, 22RV1 cells were 
cultured and treated with or without 100 µM RSV for up to 24 hours and harvested every 
four hours. Treatment at 100 µM was chosen as is it exhibited the greatest 
downregulatory effect on UBE2C at the mRNA level (Figure 5a), and findings by Wilson 
et al.20 using same cell line previously showed significantly decreased AR-V7 proteins at 
this concentration. Successful gel to membrane transfer was verified using Ponceau S 
total protein stain as seen in figure 6b, and Western blotting was conducted with 
antibodies against DBC1, AR-V7, and CHIP as target proteins (Figure 6a). GAPDH 
served as an internal loading control.  
As seen in figures 6a and 6c, DBC1 protein bands in the samples treated with 
RSV showed a gradual decrease during the first 16 hours post-treatment to around one 
third of the intensity of the untreated sample. At 20 hours post-treatment, DBC1 bands 
begin to increase again, ultimately reaching an intensity around 86% of the control at 24 
hours (Figure 6c). Together with results from the previous experiment, this overall 
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decrease in band intensity suggests that treatment with RSV post-transcriptionally 
downregulates levels of DBC1.  
As seen in figures 6a and 6d, AR-V7 protein bands showed a distinctive increase 
in intensity from the control sample to the first treated sample collected at 4 hours post-
treatment, suggesting a brief upregulation of AR-V7 proteins upon initial exposure to 
RSV. As expected for a positive control and consistent with data obtained in other 
studies20, all subsequent samples collected at 8- to 24-hours post-treatment displayed a 
gradual decrease in AR-V7 proteins (Figure 6d). After normalization to GAPDH, CHIP 
protein bands appeared to remain constant in each of the treated samples when compared 
to those in the untreated sample, suggesting that levels of CHIP proteins are additionally 
unaffected by RSV (Figures 6e).  
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Figure 6. Effects of RSV on DBC1, AR-V7, and CHIP protein levels over 24 hours. 
22RV1 cells were cultured and treated with or without 100µM RSV for up to 24 hours. Cells 
were harvested every 4 hours and whole cell lysates were prepared and quantified. 50 µg of total 
protein per sample was separated via (5%, 10%) SDS-PAGE and transferred to nitrocellulose 
membranes. Western blotting was conducted using antibodies for DBC1, AR-V7, and CHIP with 
GAPDH serving as loading control (A). Protein band intensities were normalized and quantified 
using ImageLab software. Gel to membrane transfer was verified using Ponceau S total protein 
stain (B). A time-course was plotted showing normalized, relative intensities of DBC1 (C), AR-
V7 (D), and CHIP (E) protein bands averaged from three independent experiments, each 
performed in duplicate (n = 3). 
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2.1 The effects of resveratrol on DBC1 protein stability 
To further investigate the mechanism behind this RSV-induced downregulation of 
DBC1 proteins, 22RV1 cells were cultured and treated with 50nM or 50µM 
cycloheximide (CHX) alone or in combination with 100 µM RSV. Cells were harvested 
at 2-, 4-, 8-, and 12-hours post-treatment, and Western blotting was conducted with 
antibodies against DBC1 and AR-V7 as target proteins using GAPDH as a loading 
control (Figure 7).  
For the cells treated with 50 nM of cycloheximide seen in figures 7a and 7b, 
DBC1 protein bands increased in intensity during the first 4 hours post-treatment to 
approximately 5-times and 3-times the levels seen in the untreated sample for the “CHX 
+ RSV” and “CHX only” groups, respectively. Over the next 8 hours these same groups 
began to steadily decrease, ultimately reaching levels just above those found in the 
untreated sample by 12-hours post-treatment (Figure 7b). As seen in figure 7c, the ARV7 
protein bands followed a similar trend to DBC1 in both groups, reaching levels about 
twice those seen in the untreated sample by 12-hours post-treatment. 
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Figure 7. 50 nM cycloheximide chase analysis showing effects of RSV on DBC1 & ARV7 
protein degradation. 
22RV1 cells were cultured and treated with 50 nM CHX alone or in combination with 100µM 
RSV. Cells were incubated for up to 12 hours and harvested at 2-, 4-, 8-, and 12-hours post-
treatment. Whole cell lysates were prepared and quantified using ImageLab. 30 µg of total 
protein per sample was separated via (5%, 10%) SDS-PAGE and transferred to nitrocellulose 
membranes. Western blotting was conducted using antibodies for DBC1 and AR-V7 with 
GAPDH used as loading control (A). Relative protein band intensities were normalized and 
quantified using ImageLab software. Band intensities for both DBC1 (B) and AR-V7 (C) proteins 
were averaged between three independent experiments, each performed in duplicate (n = 3), and 
plotted as a time-course.  
 
When treated with the higher 50 µM concentration of CHX detailed below in 
figures 8a and 8b, DBC1 proteins in the “CHX only” group showed an immediate 
decrease to ~60% of the control sample at 2-hours post-treatment. The levels then 
increased to well above those in the control sample at 4-hours and gradually began 
29 
decreasing to ~45% by 12-hours post-treatment. In the group treated with both CHX and 
RSV, the levels of DBC1 remained relatively unchanged across all 12 hours, the 
exception being the sample at 4-hours post-treatment which, again, increased to above the 
levels in the control.  
        As seen in figure 8c, levels of AR-V7 proteins in both the “CHX only” and “CHX + 
RSV” groups remained relatively identical to each other at each time interval. As a 
positive control, this trend is inconsistent with findings obtained under identical 
experimental parameters by Wilson et al.20, who reported increased AR-V7 degradation 
in samples treated with RSV. At 8-hours post-treatment, protein levels of AR-V7 in both 
groups began to decrease steadily, reaching approximately 50% of basal levels by hour 
12. Given the inconsistencies to reported findings in other studies and the lack of a viable 
positive control, only two experiments were run at 50 µM CHX and protein stability 
results at both concentrations were inconclusive.  
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Figure 8. 50 µM cycloheximide chase analysis showing effects of RSV on DBC1 & ARV7 
protein degradation. 
22RV1 cells were cultured and treated with 50 µM CHX alone or in combination with 100µM 
RSV. Cells were incubated for up to 12 hours and harvested at 2-, 4-, 8-, and 12-hours post-
treatment. Whole cell lysates were prepared and quantified using ImageLab. 30 µg of total 
protein per sample was separated via (5%, 10%) SDS-PAGE and transferred to nitrocellulose 
membranes. Western blotting was conducted using antibodies for DBC1 and AR-V7 with 
GAPDH used as loading control. (A). Relative protein band intensities were normalized and 
quantified using ImageLab software. Band intensities for both DBC1 (B) and AR-V7 (C) proteins 
were averaged between two independent experiments (n = 2) and plotted as a time-course. 
 
3.1 The effects of resveratrol on the mRNA levels of CDH1 and CDH2 
In a recent study, it was shown that DBC1 acts as an essential coactivator required 
for the expression of many ARV7-specific target genes including CDH2.6 In addition to 
this, CDH2 or N-cadherin expression during the epithelial-to-mesenchymal transition 
(EMT) is reciprocally paired to that of CDH1—a gene which encodes the primary cell-
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cell adhesion molecule in epithelial cells known as E-cadherin—though the specific 
mechanisms behind this link have yet to be discovered.17 Although my previous findings 
have shown that RSV downregulates protein levels of DBC1, it has not been determined 
whether RSV has any effect on the expression of N-cadherin in prostate cancer cells and 
if such an effect would be reflected in E-cadherin expression. 
In order to investigate the effects of RSV on the mRNA levels of CDH1 and 
CDH2, 22RV1 cells were again cultured and treated with or without 25-100µM serial 
dilutions of RSV for a period of 24 hours. qPCR was performed and the housekeeping 
gene GAPDH was multiplexed with the TaqMan probes for the genes of interest to 
normalize mRNA expression (Figure 9). As seen in figure 9a, mRNA levels of CDH2 
exhibited a statistically significant and dose-dependent decrease at 25, 50, 75, and 100 
µM RSV when compared to those in the untreated sample (p < 0.01). This indicates that 
treatment with RSV downregulates expression of CDH2 at the mRNA level.  
Under the same conditions seen in figure 9b, mRNA levels of CDH1 followed a 
reciprocal trend to that of CDH2, exhibiting a dose-dependent increase with increasing 
concentrations of RSV. Unlike CDH2, however, mRNA levels of CDH1 were only 
shown to be significantly different from the untreated sample at concentrations of 50, 75, 
and 100 µM RSV. This suggests RSV is capable of regulating both CDH1 and CDH2 
mRNA levels. Additionally, morphological changes in the cells could be observed at 
RSV concentrations of 50 µM and higher. With increasing concentration, the number of 
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cellular extensions and overall size of the cells showed a marked decrease, while overall 
cytoplasmic granularity, cell detachment, and cell death appeared to an increasing degree. 
Figure 9. Effect of increasing concentrations of RSV on CDH1 & CDH2 mRNA levels. 
22RV1 cells were cultured and treated with serial dilution of 25-100µM RSV for 24 hours. qPCR 
was performed in quadruplicate with GAPDH as endogenous control in multiplex with the target 
genes. Quantities of target mRNAs relative to untreated controls were calculated by ΔΔCT 
method and expressed as mean +/- SEM with CT SD <0.1. Graphs show results from three 
independent experiments (n = 3). Statistical significance was determined by post-hoc Tukey HSD 
multiple comparisons analysis following statistically significant 1-way ANOVA: *, p<0.01; **, 
p<0.001. Relative levels of CDH2 mRNA showing significant decreases in all treatment groups 
when compared with the control group (A). Relative levels of CDH1 mRNA as showing 
significantly increased levels at 50, 75, and 100µM RSV (B).  
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3.2 RSV effects on EMT-associated E- & N-cadherin proteins 
In order to investigate whether the effects of RSV on CDH2 and CDH1 mRNA 
are reflected at the protein level, 22RV1 cells were again treated with or without 100 µM 
RSV for up to 24 hours and harvested every four hours. Successful gel to membrane 
transfer was verified using Ponceau S total protein stain seen in figure 10b, and Western 
blotting was conducted with antibodies against both N-cadherin and E-cadherin, using 
GAPDH as a loading control.  
As seen in figures 10a and 10c, N-cadherin protein levels remained relatively 
unchanged during the first 12 hours post-treatment with RSV. Consistent with the 
previously observed downregulation of CDH2 mRNA levels, protein levels of N-
cadherin at 16- and 20-hours post treatment showed a gradual decline with approximately 
50% decrease in intensity by 24 hours when compared to the untreated sample (Figure 
10c). This indicates that treatment with RSV downregulates N-cadherin at the both the 
protein and mRNA levels.  
Also consistent with previous results showing upregulation at the mRNA level, 
protein levels of E-cadherin exhibited a marked increase at 4-hours post-treatment and 
continued to increase to approximately 2.5 times the basal levels at hour 16 (Figure 10d). 
By 20-hours post-treatment, protein levels begin to decrease again, though they remain 
approximately 1.5 times basal levels by hour 24. This indicates RSV upregulates E-
cadherin at both the mRNA and protein levels while downregulating levels of N-cadherin 
mRNA and proteins. As observed in the previous experiment, a dramatic change in cell 
morphology also began to occur with increasing incubation periods in the treatment 
media. Slight cytoplasmic granulation and reduction in size appeared to begin at around 
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8-hours post-treatment with a marked increase in plate detachment and cell death 
occurring by hour 12.  
Figure 10. Effects of RSV on N-cadherin & E-cadherin protein levels over 24 hours. 
22RV1 cells were cultured and treated with or without 100µM RSV for up to 24 hours. Cells 
were harvested every 4 hours and whole cell lysates were prepared and quantified. Protein band 
intensity was averaged from 3 independent experiments (n = 3). 50 µg of total protein per sample 
was separated via SDS-PAGE and transferred to nitrocellulose membranes. Western blotting was 
conducted using antibodies for N-cadherin and E-cadherin with GAPDH serving as loading 
control (A). Gel to membrane transfer was verified using Ponceau S total protein stain (B). A 
time-course was plotted showing normalized, relative intensities of N-cadherin (C) and E-
cadherin (D) protein bands averaged from three independent experiments, each performed in 
duplicate (n = 3). 
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DISCUSSION 
 
As of 2019, there are still no reliable curative treatments available for patients 
diagnosed with CRPC.1 In over 90% of cases, development of castration-resistance in 
prostate cancer is accompanied by a shift to a more aggressive and metastatic cancer cell 
behavior which is highly lethal and quickly spreads to other areas of the body.12 The most 
common cause of progression to CRPC detected in over 60% of cases is upregulation of 
AR-V7, which does not respond to any form of hormone therapy currently used and has 
been associated with decreased patient survival and shorter progression time to 
CRPC.7,12,26 Clearly for the many patients who are ARV7-positive and those with CRPC, 
there is an urgent need for novel treatment options which do not rely upon androgen 
deprivation and can specifically target AR-V7.  
One such compound with the potential to target AR-V7 is resveratrol, which was 
previously shown to reduce AR-V7 protein levels in prostate cancer cells by enhancing 
its polyubiquitination and subsequent proteasomal degradation.20 Within this study, I 
explored potential mechanisms for this increased polyubiquitination of ARV7 by RSV. 
Specifically, my investigation focused on CHIP and DBC1, as well as E- and N-
cadherins given that they have been implicated in recent studies to play a role in the 
degradation of AR-V7 and the epithelial-to-mesenchymal transition, respectively.6,16  
Given the lack of knowledge regarding the effect of resveratrol on DBC1, I 
hypothesized that RSV may increase polyubiquitination and degradation of AR-V7 by 
affecting relative levels of CHIP ubiquitin ligase and/or DBC1, which competes with it 
for binding to AR-V7.25 Following from this, I also hypothesized that treatment with 
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RSV would decrease levels of CDH2/N-cadherin in PCa cells, given that it is a target 
gene of AR-V7 and requires DBC1 for its expression.6 Furthermore, the fact that 
CDH1/E-cadherin expression is inversely tied to that of N-cadherin during EMT lead me 
to surmise that E-cadherin levels should also increase as a result of resveratrol 
treatment.17 
Any potential findings which could be linked to regulation of EMT in PCa are 
particularly worthy of investigating, as this process has proven to be crucial to cancer cell 
metastasis and progression to CRPC.16 So as to establish cellular conditions in vitro 
which closely approximate most clinical cases of CRPC, my research was conducted 
using 22RV1 cells—a cell line comprised of human CRPC cells which endogenously 
express both high levels of AR-V7 and low levels of AR-FL.27 
In order to determine whether treatment with resveratrol affects the expression of 
DBC1, I first looked for potential regulation occurring at the mRNA level. To this end, 
22RV1 cells were treated with serial dilutions of RSV ranging from 0 – 100 µM and 
incubated for a period of 24 hours. For UBE2C, a target gene of AR-V7 and not AR-FL21 
acting as the positive control, (Figure 5a) results showed a statistically-significant and 
dose-dependent reduction in mRNA levels with increasing RSV concentration. This was 
consistent with findings made in another study and suggests that the RSV-mediated 
decrease of ARV7 proteins had been replicated in my experiment.20 As mentioned 
previously, UBE2C is commonly dysregulated to increased levels in the advanced stages 
of over 27 different forms of cancer.21,23 In PCa, increased expression of UBE2C is 
directly correlated with increased AR-V7 expression21 and has been associated with 
shorter overall survival (OS) times, poorer clinical outcomes, and can indicate tumor 
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progression.23 The reduction in UBE2C mRNA levels after RSV treatment shown in this 
study may provide a relevant avenue for future research as it is a therapeutic target in 
many different cancers.23 Results seen in figure 5b showed that under the same 
conditions, mRNA levels of DBC1 were unaffected by treatment with RSV. These 
findings suggest that the increased polyubiquitination and degradation of AR-V7 induced 
by resveratrol are likely not the result of downregulation of DBC1 occurring at the 
mRNA level.  
Given that CHIP upregulation or DBC1 downregulation could both potentially 
result in enhanced polyubiquitination of AR-V7, I investigated the effects of RSV on 
protein levels of DBC1, CHIP, and AR-V7 (Figure 6). To this end, 22RV1 cells were 
treated with or without 100 µM RSV and collected every 4 hours to monitor incubation 
periods for up to 24 hours. Results from western blotting experiments (Figure 6c) showed 
that DBC1 protein levels decrease steadily over time with RSV treatment. Somewhat 
unexpectedly, DBC1 levels did begin to increase again at 20- and 24-hours post 
treatment, though not to baseline levels found in the untreated sample. One potential 
explanation for this may be the degradation of resveratrol within the treatment media 
after ~20 hours. Growth media used to prepare treatments in this study was kept at 
physiological pH of 7.4, and research on the chemical stability of resveratrol under in 
vitro conditions has shown that degradation occurs exponentially at pH > 6.8.28 This is 
consistent with the fact that the relative decrease in DBC1 protein levels is greatest at 4-
hours post-treatment and appears to drop off with time. Unfortunately, this relative 
instability at physiological pH also demonstrates what is currently one of the major 
obstacles to the use of RSV as a potential treatment. Not only is it chemically unstable in 
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conditions within the body, but like many phytochemicals, RSV has a very low 
bioavailability in human tissues and would require constant administration in high doses 
to maintain therapeutic concentrations.29,30 While RSV is rapidly absorbed when 
administered orally, it is quickly conjugated and metabolized by the first-pass effect and 
only trace amounts of unaltered RSV have been shown to make it into systemic 
tissues.29,31 In an effort to combat this problem, a synthetic derivative of RSV known as 
pterostilbene (PTS) has been developed which, in several studies, has been shown to 
exhibit both higher bioavailability and stronger pharmacological activity than RSV.29,30,32  
As expected in the positive control, protein levels of AR-V7 showed a steady 
decrease over time with RSV, but only after an initial increase was observed immediately 
following treatment (Figure 6d). Aside from this increase, these results were consistent 
with those obtained in a separate study which used the same cell line.20 A survey of the 
relevant literature revealed no functions or interactions which might explain the initial 
upregulation of AR-V7 proteins upon treatment with RSV, however the regulatory 
mechanisms which drive the alternative splicing and production of AR-V7 are not 
currently well understood. In figure 6e it was also shown that levels of CHIP protein 
remain constant in the presence of RSV. Together, these results indicate that RSV-
mediated downregulation also occurs post-transcriptionally in DBC1, albeit with an 
earlier time of onset by a few hours. Concurrently, levels of CHIP protein appeared to be 
unaffected by treatment with RSV. This further supports my hypothesis that RSV 
increases AR-V7 polyubiquitination via downregulation of DBC1 proteins and not via 
upregulation of CHIP. Though all data gathered over the course of my investigation 
supported and was consistent with this hypothesis, further research would be required to 
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state conclusively that this is the case or that it is the sole mechanism involved. With the 
exceedingly wide range of anti-cancer effects attributed to RSV across a variety of 
different cancers, it is well within the realm of possibility that more than one of them 
could be contributing to the increased polyubiquitination of AR-V7.24,29,31,33-35  
One major limitation in my study occurred when attempting to further investigate 
the mechanism for RSV-induced downregulation of DBC1 protein. In using 
cycloheximide—a potent inhibitor of protein synthesis in eukaryotic cells—to track 
protein degradation over time, I was ultimately unable to determine whether RSV has any 
effects on DBC1 or AR-V7 protein stability. Results at 50 nM CHX (Figures 7b-c) 
showed DBC1 proteins increasing over time and AR-V7 proteins following a similar 
trend to DBC1 in both groups, reaching levels about twice those seen in the untreated 
sample by 12-hours post-treatment. Because this was inconsistent with results obtained in 
previous experiments and seemed to indicate an increase in protein levels following 
treatment with a protein synthesis inhibitor, the experiment was deemed inconclusive. 
Given that the EC50 for CHX to inhibit protein synthesis can vary depending on cell-type 
and the specific conditions in vitro, the experiment was re-attempted at a higher 
concentration of CHX. Results at 50 µM CHX (Figures 8b and 8c) showed DBC1 
seemingly unaffected over time and levels of AR-V7 in both the “CHX only” and “CHX 
+ RSV” groups remaining relatively identical to each other at each time interval. As the 
positive control, this trend is inconsistent with findings obtained under identical 
experimental parameters in Wilson et al.20, who reported increased AR-V7 degradation in 
samples treated with RSV. 20Also inconsistent with that study, which showed a 50% 
reduction in AR-V7 by 2-hours post-treatment, AR-V7 levels in my experiment remained 
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roughly equal to that of the control sample until hour 8, when they began a gradual 
decrease and did not reach ~50% until 12-hours post-treatment.20 Given these 
inconsistencies with the literature at both concentrations and the lack of viable positive 
control data, only two experiments were run at 50 µM CHX and I was unable to draw any 
conclusions regarding the effects of RSV on DBC1 or AR-V7 protein stability. One 
potential explanation for these inconsistencies is that RSV somehow interferes with 
cycloheximide’s ability to block protein synthesis. In at least one other study, treatment 
with RSV in vitro was shown to greatly reduce cycloheximide-induced cell death 
resulting from inhibited protein synthesis.36 Another factor which may have contributed 
to the inconsistency is the slight overlap of the protein bands on the blot, which made it 
difficult to consistently and reliably quantify individual bands. 
CDH2 or N-cadherin expression during the epithelial-to-mesenchymal transition 
is reciprocally paired to that of CDH1—a gene which encodes the primary cell-cell 
adhesion molecule in epithelial cells known as E-cadherin.17,37 Finding potential cancer 
treatments which can affect these EMT marker molecules are particularly important 
given that, alongside the loss of E-cadherin, increased levels of N-cadherin have shown 
to be one of the primary drivers of progression to metastasis and the development of 
castration-resistance in PCa.6,16-18 In order to investigate the effects of RSV on mRNA 
levels of CDH1 (E-cadherin) and CDH2 (N-cadherin), 22RV1 cells were treated with 
serial dilutions of RSV ranging from 0 – 100 µM and incubated for a period of 24 hours. 
qPCR results (Figure 9a) showed a statistically significant and dose-dependent decrease 
in levels of CDH2 mRNA with increasing concentrations of RSV. This suggests that 
RSV downregulates CDH2 expression at the mRNA level. Consistent with this finding 
41 
and the known reciprocal expression patterns of CDH1 and CDH2, results (Figure 9b) 
showed that levels of CDH1 mRNA were increased in a statistically significant and dose-
dependent manner with RSV concentration. This indicates that RSV can both 
downregulate levels of CDH2 mRNA and upregulate levels of CDH1 mRNA. Having 
previously established a decrease in DBC1 protein levels with RSV treatment, these 
findings support my hypothesis that RSV-induced depletion of DBC1 and a resulting 
reduction in AR-V7 proteins would lead to decreased levels of N-cadherin. More 
importantly, it suggests that RSV is capable of decreasing the expression of N-cadherin 
while simultaneously increasing expression of E-cadherin. Given that basal levels of 
CDH1 were greater than CDH2 in these cells both before and after treatment, this 
indicates that RSV may be inhibiting the cadherin switch that makes up the crucial first 
step in the initiation of EMT.17,19,37  
In order to determine whether the effects of RSV impact protein levels of N- and 
E-cadherin, 22RV1 cells were again treated with or without 100 µM RSV and collected 
every 4 hours to monitor incubation periods for up to 24 hours (Figure 10a). Western 
blotting results (Figure 10c) showed that protein levels of N-cadherin remain steady until 
around 16-hours post-treatment with RSV, at which point they begin to decrease steadily. 
This delayed but present reduction in N-cadherin proteins is consistent with the observed 
decrease in mRNA levels of CDH2, given the additional time it would take for 
transcriptional changes to be reflected at the protein level. Together, this shows that 
treatment with RSV can downregulate N-cadherin expression at both the protein and 
mRNA levels. This is particularly relevant given that, alongside the loss of E-cadherin, 
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increased expression of N-cadherin is one of the primary drivers of metastasis and the 
development of castration-resistance in CRPC.16,18  
Results (Figure 10d) additionally showed an immediate and marked increase in E-
cadherin proteins after only 4 hours of RSV exposure. These levels continued to increase 
over the next 12 hours, albeit more gradually, before reaching peak levels at around 16-
hours post-treatment. This was consistent with the previously shown increase in CDH1 
mRNA and indicates that RSV can also upregulate expression of E-cadherin at both the 
mRNA and protein levels. The large difference in onset time for this effect when 
compared to N-cadherin, however, implies that RSV may mediate its effect(s) on E-
cadherin through another mechanism. While an upregulation of E-cadherin at the mRNA 
level is present as well, the strength and onset of the protein increase at 4-hours post-
treatment (Figure 10d) may imply the existence of additional upregulatory effects which 
act on multiple levels. In several other late-stage cancers such as gastric, colorectal, and 
lung cancer, numerous studies have shown that RSV is capable of increasing E-cadherin 
at both the mRNA and protein level via downregulation of SNAI1, a nuclear transcription 
factor which inhibits E-cadherin expression during EMT.33,35 In these studies, it was 
reported that this increase in E-cadherin was also accompanied by significant changes in 
cell morphology and suppression of the EMT phenotype.33,35 This is consistent with the 
morphological changes in the CRPC cells that were observed in my experiment. There 
are, however, additional protein markers which characterize EMT that require 
investigating to conclude for certain if RSV can affect the process itself.  
 Similar to the levels of DBC1 protein, E-cadherin proteins also appeared to begin 
decreasing between 16- and 20-hours post-treatment, though they remain at increased 
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levels when compared to the untreated sample at 24-hours post-treatment. This is 
consistent with my hypothesis that RSV treatment reciprocally affects levels of N- and E-
cadherin, and supports the likelihood that the increase in DBC1 proteins after ~20 hours 
(Figure 6c) is the result of RSV degradation in the growth media. 
This effect is nevertheless relevant, as the loss of E-cadherins and epithelial cell-
to-cell adhesion is what is primarily characterized by the epithelial-to-mesenchymal 
transition, and cancer cells that undergo this transition show significantly increased 
migratory capacity, invasiveness, and resistance to apoptosis.17,18 Having established that 
downregulation of DBC1 proteins does occur with RSV treatment, these findings lend 
further support to my hypothesis that RSV-induced depletion of DBC1 and the resulting 
reduction in AR-V7 proteins may decrease the expression of N-cadherin and increase the 
expression of E-cadherin. As stated previously, this effect holds the potential to be highly 
relevant for future studies researching treatment of ARV7-positive CRPC as it suggests 
RSV may be able inhibit the cadherin switch during EMT that is required for cancer cells 
to gain their metastatic potential. Because the basal levels of E-cadherin still exceeded 
those of N-cadherin in the cancer cells in this study, they are still characteristically 
epithelial and therefore this effect represents a potential inhibition of EMT rather than 
induction of MET. In any case, the importance of developing the kinds treatments which 
reduce metastatic potential cannot be overstated as currently over 90% of mortalities 
linked to any form of cancer arise due to the metastasis and growth of secondary 
tumors.34 
Aside from the inconclusive results regarding DBC1 and AR-V7 protein 
degradation, one more major limitation/potential source of uncertainty was encountered 
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during the course of this study. In performing western blots measuring protein levels of 
DBC1, three distinct signal bands at ~88, 70, and 60 kDa were consistently detected on 
the membranes when only one is reported in MCF7 cells by the manufacturer of the 
primary antibody (Figure 11). There are no currently known isoforms or splice-variants 
of DBC1, so only the strongest signal present at the reported molecular weight of 88 kDa 
was quantified and reported in this study. Given that the other bands appeared at lower 
molecular weights, they could represent artifacts of DBC1 degradation, however this 
typically presents as one long smeared band these appear as discrete and separate signals. 
Furthermore, degradation product signals would typically reflect the intensity of the 
primary band, yet expression trends for these are consistent and distinct from those of the 
primary band or the other signal, so I believe this explanation to be unlikely. It is also 
possible that they result from overloading the gel with too much protein at 50 µg, 
however they were still present when 20 and 30 µg of protein were loaded, so this 
explanation is also not very likely. They are detected by other researchers using 22RV1 
cells in the same lab and MCF7 cell lysates run in the same gel show only the primary 
band, so it is not likely due to personal laboratory technique and may simply be an effect 
specific to the 22RV1 cell line.  
Figure 11. Western blot showing triple DBC1 protein bands at 20 and 50µg in 22RV1 
cells treated w/ or w/o 100 µM RSV. 
45 
In conclusion, this study has demonstrated in prostate cancer cells that treatment 
with resveratrol post-transcriptionally downregulates protein levels of DBC1 while 
reducing levels of AR-V7 protein and the subsequent expression of its target genes. 
Protein levels of CHIP ligase were unaffected by treatment with RSV, suggesting that it 
may mediate enhanced AR-V7 polyubiquitination and proteasomal degradation by 
decreasing levels of DBC1. It was demonstrated that RSV treatment causes 
downregulation of N-cadherin mRNA and protein levels in a statistically significant and 
dose-dependent manner. RSV was also shown to simultaneously increase levels of E-
cadherin mRNA and proteins in a statistically significant and dose-dependent manner, 
suggesting it may be capable of inhibiting the epithelial-to-mesenchymal transition in 
CRPC cells. Together, these findings have indicated that RSV is worthy of further study 
as a promising therapeutic option for patients diagnosed with ARV7-positive prostate 
cancer and CRPC. 
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